Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with Trauma

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 2, 2013, Pages 237-255

  Esposito, Emanuela ^a   Cuzzocrea, Salvatore ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Acylethanolamines; Inflammation; PPAR alpha; SCI

Indexed keywords

ANANDAMIDE; DEXAMETHASONE; DICLOFENAC; FATTY ACID AMIDASE INHIBITOR; HYDROCORTISONE; MONOCYTE CHEMOTACTIC PROTEIN 2; N METHYL DEXTRO ASPARTIC ACID; OLEAMIDE; PALMIDROL; PLACEBO; PREGABALIN; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ARTICLE; ATOPIC DERMATITIS; CARPAL TUNNEL SYNDROME; CELL DAMAGE; DEPRESSION; EDEMA; HUMAN; HYPOTHERMIA; INFLAMMATION; INJURY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LOCOMOTION; LOW DRUG DOSE; MULTICENTER STUDY (TOPIC); NECROSIS; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; OPEN ANGLE GLAUCOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; SKIN DISEASE;

EID: 84876868085     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955713804805184     Document Type: Article

References (169)

1. Petrosino, S.; Cristino, L.; Karsak, M.; Gaffal, E.; Ueda, N.; Tüting, T.; Bisogno, T.; De Filippis, D.; D'Amico, A.; Saturnino, C.; Orlando, P.; Zimmer, A.; Iuvone, T.; Di Marzo, V. Protective role of palmitoylethanolamide in contact allergic dermatitis. Allergy, 2010, 65(6), 698-711.
2. Re, G.; Barbero, R.; Miolo, A.; Di Marzo, V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: Potential use in companion animals. Vet. J., 2007, 173(1), 23-32.
3. Chapman, K.D. Occurrence, metabolism, and prospective functions of N-acylethanolamines in plants. Prog. Lipid Res., 2004, 43(4), 302-327.
4. Schmid, H.H.; Berdyshev, E.V. Cannabinoid receptor-inactive Nacylethanolamines and other fatty acid amides: metabolism and function. Prostaglandins Leukot. Essent. Fatty Acids, 2002, 66(2-3), 363-376.
5. Petrosino, S.; Di Marzo, V. Anandamide and Other Acylethanolamides. Chapter 5 In: Tettamanti G and Goracci G (eds.), Handbook of neurochemistry and molecular neurobiology. Neural Lipids, 3rd edition, Springer, 2009 pp.75-98.
6. Petrosino, S.; Iuvone, T.; Di Marzo, V. N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. Biochimie, 2010, 92(6), 724-727.
7. Ueda, N.; Tsuboi, K.; Uyama, T. N-acylethanolamine metabolism with special reference to 4 N-acylethanolamine-hydrolyzing acid amidase (NAAA). Prog. Lipid Res., 2010, 49(4), 299-315.
8. Bisogno, T.; Maurelli, S.; Melck, D.; De Petrocellis, L.; Di Marzo, V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem., 1997, 272(6), 3315-3323.
9. Jacobsson, S.O.; Fowler, C.J. Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide. Br. J. Pharmacol., 2001, 132(8), 1743-17454.
10. Di Marzo, V.; Bisogno, T.; De Petrocellis, L.; Melck, D.; Martin, B.R. Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids. Curr. Med. Chem., 1999, 6(8), 721-744.
11. Facci, L.; Dal Toso, R.; Romanello, S.; Buriani, A.; Skaper, S.D.; Leon, A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci., 1995, 92(8), 3376-3380.
12. Lambert, D.M.; Vandevoorde, S.; Jonsson, K.O.; Fowler, C.J. The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr. Med. Chem., 2002, 9(6), 663-674.
13. Lambert, D.M.; Di Marzo, V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr. Med. Chem., 1999, 6(8), 757-773.
14. Showalter, V.M.; Compton, D.R.; Martin, B.R.; Abood, M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther., 1996, 278(3), 989-999.
15. Sugiura, T.; Kondo, S.; Kishimoto, S.; Miyashita, T.; Nakane, S.; Kodaka, T.; Suhara, Y.; Takayama, H.; Waku, K. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem., 2000, 275(1), 605-612.
16. Jaggar, S.I.; Hasnie, F.S.; Sellaturay, S.; Rice, A.S. The antihyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain, 1998, 76(1-2), 189-199.
17. Calignano, A.; La Rana, G.; Giuffrida, A.; Piomelli, D. Control of pain initiation by endogenous cannabinoids. Nature, 1998, 394 (6690), 277-281.
18. Conti, S.; Costa, B.; Colleoni, M.; Parolaro, D.; Giagnoni, G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br. J. Pharmacol., 2002, 135(1), 181-7.
19. Naccarato, M.; Pizzuti, D.; Petrosino, S.; Simonetto, M.; Ferigo, L.; Chiodo Grandi, F.; Pizzolato, G.; Di Marzo, V. Possible Anandamide and Palmitoylethanolamide involvement in human stroke. Lipids Health Dis., 2010, 9(1), 47.
20. Moriconi, A.; Cerbara, I.; Maccarrone, M.; Topai, A. GPR55: Current Knowledge and Future Perspectives of a Purported Type-3 Cannabinoid Receptor. Curr. Med. Chem., 2010, 17(14), 1411-1429.
21. LoVerme, J.; Fu, J.; Astarita, G.; La Rana, G.; Russo, R.; Calignano, A.; Piomelli, D. The nuclear receptor peroxisome proliferatoractivated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol., 2005, 67(1), 15-19.
22. O'Sullivan, S.E.; Kendall, D.A. Cannabinoid activation of peroxisome proliferator-activated receptors: Potential for modulation of inflammatory disease. Immunobiology, 2010, 215(8), 611-616.
23. Levi-Montalcini, R.; Skaper, S.D.; Dal Toso, R.; Petrelli, L.; Leon, A. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci., 1996, 19(11), 514-520.
24. Cerrato, S.; Brazis, P.; Miolo, A.; della Valle, F.; Puigdemont, A. Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNF release from canine skin mast cells. Vet. Immunol. Immunopathol., 2010, 133(1), 9-15.
25. Hoareau, L.; Buyse, M.; Festy, F.; Ravanan, P.; Gonthier, M.P.; Matias, I.; Petrosino, S.; Tallet, F.; d'Hellencourt, C.L.; Cesari, M.; Di Marzo, V.; Roche, R. Anti-inflammatory Effect of Palmitoylethanolamide on Human Adipocytes. Obesity (Silver Spring), 2009, 17(3), 431-438.
26. Skaper, S.D.; Buriani, A.; Dal Toso, R.; Petrelli, L.; Romanello, S.; Facci, L.; Leon, A. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc. Natl. Acad. Sci. U S A., 1996, 93(9), 3984-3989.
27. Costa, B.; Conti, S.; Giagnoni, G.; Colleoni, M. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br. J. Pharmacol., 2002, 137(4), 413-420.
28. Cerrato, S.; Brazis, P.; della Valle, M.F.; Miolo, A.; Petrosino, S.; Di Marzo, V.; Puigdemont, A. Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs. Vet. J., 2012, 191(3), 377-382.
29. Wise, L.E.; Cannavacciulo, R.; Cravatt, B.F.; Marun, B.F.; Lichtman, A.H. Evaluation of fatty acid amides in the carrageenan-induced paw edema model. Neuropharmacology, 2008, 54(1), 181-188.
30. Murillo-Rodríguez, E.; Vázquez, E.; Millán-Aldaco, D.; PalomeroRivero, M.; Drucker-Colin, R. Effects of the fatty acid amide hydrolase inhibitor URB597 on the sleep-wake cycle, c-Fos expression and dopamine levels of the rat. Eur. J. Pharmacol., 2007, 562(1-2), 82-91.
31. D'Agostino, G.; La Rana, G.; Russo, R.; Sasso, O.; Iacono, A.; Esposito, E.; Mattace Raso, G.; Cuzzocrea, S.; Lo Verme, J.; Piomelli, D.; Meli, R.; Calignano, A. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kB nuclear signalling in dorsal root ganglia. Eur. J. Pharmacol., 2009, 613(1-3), 54-59.
32. Sasso, O.; La Rana, G.; Vitiello, S.; Russo, R.; D'Agostino, G.; Iacono, A.; Russo, E.; Citraro, R.; Cuzzocrea, S.; Piazza, P.V.; De Sarro, G.; Meli, R.; Calignano, A. Palmitoylethanolamide modulates pentobarbital-evoked hypnotic effect in mice Involvement of allopregnanolone biosynthesis. Eur. Neuropsychopharmacol., 2010, 20(3), 195-206.
33. Schomacher, M.; Müller, H.D.; Schwab, S.; Sommer, C.; Schäbitz, W.R. Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia. Brain Res., 2008, 1240, 213-220.
34. Scarampella, F.; Abramo, F.; Noli, C. Clinical and histological evaluation of an analogue of palmitoylethanolamide, PLR 120 (comicronized Palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study. Vet. Dermatol., 2001, 12(1), 29-39.
35. Guida, G.; de Martino, M.; de Fabiani, A.; Cantieri, L.; Alexandre, A.; Vassallo, G.M.; Rogai, M.; Lanaia, F.; Petrosino, S. La palmitoiletanolamida (Normast®) en el dolor neuropático crónico por lumbociatalgia de tipo compresivo: estudio clínico multicéntrico. Dolor, 2010, 25, 35-42.
36. Canteri, L.; Petrosino, S.; Guida, G. Reducción del consumo de antiinflamatorios y analgésicos en el tratamiento del dolor neuropático crónico en pacientes afectados por lumbociatalgia de tipo compresivo y en tratamiento con Normast® 300 mg. Dolor, 2010, 25(4), 227-234.
37. Conigliaro, R.; Drago, V.; Foster, P.S.; Schievano, C.; Di Marzo, V. Use of the palmitoylethanolamide in the entrapment neuropathy of the median in the wrist. Minerva Med., 2011, 102(2), 141-147.
38. Desio, P. Associazione tra pregabalin e palmitoiletanolamide per il trattamento del dolore neuropatico. Pathos, 2010, 17(4).
39. Eberlein, B.; Eicke, C.; Reinhardt, H.W.; Ring, J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J. Eur. Acad. Dermatol. Venereol., 2008, 22(1), 73-82.
40. Coburn, A.F.; Graham, C.E.; Haninger, J. The effect of egg yolk in diets on anaphylactic arthritis (passive Arthus phenomenon) in the guinea pig. J. Exp. Med., 1954, 100(5), 425-435.
41. Long, D.A.; Martin, A.J. Factor in arachis oil depressing sensitivity to tuberculin in B.C.G.-infected guineapigs. Lancet, 1956, 270 (6921), 464-6.
42. Kuehl, F.A.Jr.; Jacob, T.A.; Ganley, O.H.; Ormond, R.E.; Meisinger, M.A.P. The identification of N-(2-hydroxyethyl)-palmitamide as a naturally occuring anti-inflammatory agent. J. Am. Chem. Soc., 1957, 79(19), 5577-5578.
43. Ganley, O.H.; Graessle, O.E.; Robinson, H.J. Anti-inflammatory activity on compounds obtained from egg yolk, peanut oil, and soybean lecithin. J. Lab. Clin. Med., 1958, 51(5), 709-714.
44. Ganley, O.H.; Robinson, H.J. Antianaphylactic and antiserotonin activity of a compound obtained from eggyolk, peanut oil and soybean lecithin. J. Allergy, 1959, 30, 415-9.
45. Benvenuti, F.; Lattanzi, F.; De Gori, A.; Tarli, P. Attività di alcuni derivati della palmitoiletanolamide sull'edema da carragenina nella zampa di ratto. Boll. Soc. Ital. Biol. Sper., 1968, 44(9), 809-813.
46. Perlik, F.; Raskova, H.; Elis, J. Anti-inflammatory properties of N(2-hydroxyethyl) palmitamide. Acta Physiol. Acad. Sci. Hung, 1971, 39(4), 395-400.
47. Masek, K.; Perlik, F.; Klima, J.; Kahlich, R. Prophylactic efficacy of N-2-hydroxyethyl palmitamide (impulsin) in acute respiratory tract infections. Eur. J. Clin. Pharmacol., 1974, 7(6), 415-419.
48. Kahlich, R.; Klima, J.; Cihla, F.; Frankova, V.; Masek, K.; Rosicky, M.; Matousek, F.; Bruthans, J. Studies on prophylactic efficacy of N-2-hydroxyethyl palmitamide (Impulsin) in acute respiratory infections. Serologically controlled field trials. J. Hyg. Epidemiol. Microbiol. Immunol., 1979, 23(1), 11-24.
49. Aloe, L.; Leon, A.; Levi-Montalcini, R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions, 1993, 39 Spec No, C145-147
50. Ito, A.; Hagiyama, M.; Oonuma, J. Nerve-mast cell and smooth muscle-mast cell interaction mediated by cell adhesion molecule-1, CADM1. J. Smooth Muscle Res., 2008, 44(2), 83-93.
51. Abraham, S.N.; St John, AL. Mast cell-orchestrated immunity to pathogens. Nat. Rev. Immunol., 2010, 10(6), 440-452.
52. Brown, J.M.; Wilson, T.M.; Metcalfe, D.D. The mast cell and allergic diseases: role in pathogenesis and implications for therapy. Clin. Exp. Allergy, 2008, 38(1), 4-18.
53. Kumar, V.; Sharma, A. Mast cells: Emerging sentinel innate immune cells with diverse role in immunity. Mol. Immunol., 2010, 48(1-3), 14-25.
54. Maurer, M.; Theoharides, T.; Granstein, R.D.; Bischoff, S.C.; Bienenstock, J.; Henz, B.; Kovanen, P.; Piliponsky, A.M.; Kambe, N.; Vliagoftis, H.; Levi-Schaffer, F.; Metz, M.; Miyachi, Y.; Befus, D.; Forsythe, P.; Kitamura, Y.; Galli, S. What is the physiological function of mast cells? Exp. Dermatol., 2003, 12(6), 886-910.
55. Metz, M.; Grimbaldeston, M.A.; Nakae, S.; Piliponsky, A.M.; Tsai, M.; Galli, S.J. Mast cells in the promotion and limitation of chronic inflammation. Immunol. Rev., 2007, 217, 304-328.
56. Moon, T.C.; St Laurent, C.D.; Morris, K.E.; Marcet, C.; Yoshimura, T.; Sekar, Y.; Befus, A.D. Advances in mast cell biology: new understanding of heterogeneity and function. Mucosal Immunol., 2010, 3(2), 111-128.
57. Puxeddu, I.; Ribatti, D.; Crivellato, E.; Levi-Schaffer, F. Mast cells and eosinophils: A novel link between inflammation and angiogenesis in allergic diseases. J. Allergy Clin. Immunol., 2005, 116(3), 531-536.
58. Galli, S.J.; Tsai, M. Mast cells in allergy and infection: Versatile effector and regulatory cells in innate and adaptive immunity. Eur. J. Immunol., 2010, 40, 1843-1851.
59. Lundequist, A.; Pejler, G. Biological implications of preformed mast cell mediators. Cell. Mol. Life Sci., 2011, 68(6), 965-975.
60. Ren, K.; Dubner, R. Interactions between the immune and nervous systems in pain. Nat. Med., 2010, 16(11), 1267-1276.
61. Bischoff, S.C. Physiological and pathophysiological functions of intestinal mast cells. Semin. Immunopathol., 2009, 31(2), 185-205.
62. Eklund, K.K. Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy. Immunol. Rev., 2007, 217, 38-52.
63. Farhadi, A.; Fields, J.Z.; Keshavarzian, A. Mucosal mast cells are pivotal elements in inflammatory bowel disease that connect the dots: stress, intestinal hyperpermeability and inflammation. World J. Gastroenterol., 2007, 13(22), 3027-3030.
64. Harvima, I.T.; Nilsson, G.; Suttle, M.M.; Naukkarinen, A. Is there a role for mast cells in psoriasis? Arch. Dermatol. Res., 2008, 300(9), 461-478.
65. Holdsworth, S.R.; Summers, S.A. Role of Mast Cells in Progressive Renal Diseases. J. Am. Soc. Nephrol., 2008, 19(12), 2254-2261.
66. Kneilling, M.; Rocken, M. Mast cells: novel clinical perspectives from recent insights. Exp. Dermatol., 2009, 18, 488-496.
67. Nautiyal, K.M.; Ribeiro, A.C.; Pfaff, D.W.; Silver, R. Brain mast cells link the immune system to anxiety-like behavior. Proc. Natl. Acad. Sci. U.S.A., 2008, 105(46), 18053-18057.
68. Navi, D.; Saegusa, J.; Liu, F.T. Mast cells and immunological skin diseases. Clin. Rev. Allergy Immunol., 2007, 33(1-2), 144-155.
69. Strbian, D.; Kovanen, P.T.; Karjalainen-Lindsberg, M.L.; Tatlisumak, T.; Lindsberg, P.J. An emerging role of mast cells in cerebral ischemia and hemorrhage. Ann. Med., 2009, 41, 438-450.
70. Theoharides, T.C.; Cochrane, D.E. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J. Neuroimmunol., 2004, 146(1-2), 1-12.
71. Theoharides, T.C; Kalogeromitros, D. The critical role of mast cells in allergy and inflammation. Ann, N Y Acad. Sci., 2006, 1088, 78-99.
72. Tore, F.; Tuncel, N. Mast cells: target and source of neuropeptides. Curr. Pharm. Des., 2009, 15(29), 3433-3445.
73. Hansen, H.S.; Moesgaard, B.; Hansen, H.H.; Petersen, G. N-Acylethanolamines and precursor phospholipids - relation to cell injury. Chem. Phys. Lipids, 2000, 108(1-2), 135-150.
74. Dawson, R.M.; Clarke, N.; Quarles, R.H. N-acylphosphatidylethanolamine, a phospholipid that is rapidly metabolized during the early germination of Pea seeds. Biochem. J., 1969, 114(2), 265-7.
75. Aneja, R.; Chadha, J.S.; Knaggs, J.A. N-Acylphosphatidylethanolamines: occurrence in nature, structure and stereochemistry. Biochem. Biophys. Res. Commun., 1969, 36(3), 401-6.
76. Gray, G.M. Phosphatidyl-(N-acyl)-ethanolamine. A lipid component of mammalian epidermis. Biochim. Biophys. Acta, 1976, 431(1), 1-8.
77. Clarke, N.G.; Hazlewood, G.P.; Dawson, R.M. Novel lipids of Butyrivibrio spp. Chem. Phys. Lipids, 1976, 17(2-3 SPEC NO), 222-232.
78. Ellingson, J.S. Identification of N-acylethanolamine phosphoglycerides and acylphosphatidylglycerol as the phospholipids which disappear as Dictyostelium discoideum cells aggregate. Biochemistry, 1980, 19(26), 6176-6182.
79. Matias, I.; Bisogno, T.; Melck, D.; Vandenbulcke, F.; Verger-Bocquet, M.; De Petrocellis, L.; Sergheraert, C.; Breton, C.; Di Marzo, V.; Salzet, M. Evidence for an endocannabinoid system in the central nervous system of the leech Hirudo medicinalis. Brain Res. Mol. Brain Res., 2001, 87(2), 145-159.
80. Epps, D.E.; Natarajan, V.; Schmid, P.C.; Schmid, H.O. Accumulation of N-acylethanolamine glycerophospholipids in infarcted myocardium. Biochim. Biophys. Acta, 1980, 618(3), 420-430.
81. Natarajan, V.; Schmid, P.C.; Reddy, P.V.; Zuzarte-Augustin, M.L.; Schmid, H.H. Occurrence of N-acylethanolamine phospholipids in fish brain and spinal cord. Biochim. Biophys. Acta, 1985, 835(3), 426-433.
82. Natarajan, V.; Schmid, P.C.; Reddy, P.V.; Zuzarte-Augustin, M.L.; Schmid, H.H. Biosynthesis of N-acylethanolamine phospholipids by dog brain preparations. J. Neurochem., 1983, 41(5), 1303-1312.
83. Moesgaard, B.; Petersen, G.; Jaroszewski, J.W.; Hansen, H.S. Age dependent accumulation of N-acyl-ethanolamine phospholipids in ischemic rat brain. A (31)P NMR and enzyme activity study. J. Lipid. Res., 2000, 41(6), 985-990.
84. Gulaya, N.M.; Volkov, G.L.; Klimashevsky, V.M.; Govseeva, N.N.; Melnik, A.A. Changes in lipid composition of neuroblastoma C1300 N18 cell during differentiation. Neuroscience, 1989, 30(1), 153-164.
85. Di Marzo, V.; De Petrocellis, L.; Sepe, N.; Buono, A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem. J., 1996, 316 (Pt 3), 977-984.
86. Schmid, H.H.; Schmid, P.C.; Natarajan, V. N-acylated glycerophospholipids and their derivatives. Prog. Lipid Res., 1990, 29(1), 1-43.
87. Kondo, S.; Sugiura, T.; Kodaka, T.; Kudo N, Waku, K.; Tokumura, A. Accumulation of various N-acylethanolamines including N-arachidonoylethanolamine (anandamide) in cadmium chloride-administered rat testis. Arch. Biochem. Biophys., 1998, 354(2), 303-310.
88. Schmid, P.C.; Kuwae, T.; Krebsbach, R.J.; Schmid, H.H. Anandamide and other N-acylethanolamines in mouse peritoneal macrophages. Chem. Phys. Lipids, 1997, 87(2), 103-110.
89. Chapman, K.D.; Tripathy, S.; Venables, B.; Desouza, A.D. N-Acylethanolamines: formation and molecular composition of a new class of plant lipids. Plant Physiol., 1998, 116(3), 1163-1168.
90. Wren, J.J.; Merryfield, D.S. Precursors of N-acylethanolamines in hen's egg-yolk lipid. Biochim. Biophys. Acta, 1965, 98(3), 589-597.
91. Muccioli, G.G.; Sia, A.; Muchowski, P.J.; Stella, N. Genetic manipulation of palmitoylethanolamide production and inactivation in Saccharomyces cerevisiae. PLoS One, 2009, 4(6), e5942.
92. Bachur, N.R.; Masek, K.; Melmon, K.L.; Udenfriend, S. Fatty acid amides of ethanolamine in mammalian tissues. J. Biol. Chem., 1965, 240, 1019-1024.
93. Kilaru, A.; Isaac, G.; Tamura, P.; Baxter, D.; Duncan, S.R.; Venables, B.J.; Welti, R.; Koulen, P.; Chapman, K.D. Lipid profiling reveals tissue-specific differences for ethanolamide lip ids in mice lacking Fatty Acid amide hydrolase. Lipids, 2010, 45(9), 863-875.
94. Borrelli, F.; Izzo, A.A. Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. Best Pract. Res. Clin. Endocrinol. Metab., 2009, 23(1), 33-49.
95. Lam, P.M.; Marczylo, T.H.; Konje, J.C. Simultaneous measurement of three N-acylethanolamides in human bio-matrices using ultra performance liquid chromatography-tandem mass spectrometry. Anal. Bioanal. Chem., 2010, 398(5), 2089-2097.
96. Zoerner, A.A.; Gutzki, F.M.; Suchy, M.T.; Beckmann, B.; Engeli, S.; Jordan, J.; Tsikas, D. Targeted stable-isotope dilution GC-MS/MS analysis of the endocannabinoid anandamide and other fatty acid ethanol amides in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2009, 877(26), 2909-2923.
97. Fonseca, B.M., Correia-da-Silva, G.; Taylor, A.H.; Lam, P.M.; Marczylo, T.H.; Konje, J.C.; Bell, S.C.; Teixeira, N.A. N-acylethanolamine levels and expression of their metabolizing enzymes during pregnancy. Endocrinology, 2010, 151(8), 3965-3974.
98. Schuel, H.; Burkman, L.J.; Lippes, J.; Crickard, K.; Forester, E.; Piomelli, D.; Giuffrida, A. N-Acylethanolamines in human reproductive fluids. Chem. Phys. Lipids, 2002, 121(1-2), 211-227.
99. Gonthier, M.P.; Hoareau, L.; Festy, F.; Matias, I.; Valenti, M.; BèsHoutmann, S.; Rouch, C.; Robert-Da Silva, C.; Chesne, S.; Lefebvre d'Hellencourt, C.; Césari, M.; Di Marzo, V.; Roche, R. Identification of endocannabinoids and related compounds in human fat cells. Obesity (Silver Spring), 2007, 15(4), 837-845.
100. Richardson, D.; Pearson, R.G.; Kurian, N.; Latif, M.L.; Garle, M.J.; Barrett, D.A.; Kendall, D.A.; Scammell, B.E.; Reeve, A.J.; Chapman, V. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res. Ther., 2008, 10(2), R43
101. Murillo-Rodriguez, E.; Désarnaud, F.; Prospéro-García, O. Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat. Life Sci., 2006, 79(1), 30-37.
102. Matias, I.; Wang, J.W.; Moriello, A.S.; Nieves, A.; Woodward, D.F.; Di Marzo, V. Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. Prostaglandins Leukot. Essent. Fatty Acids, 2006, 75(6), 413-8.
103. Chen, J.; Matias, I.; Dinh, T.; Lu, T.; Venezia, S.; Nieves, A.; Woodward, D.F.; Di Marzo, V. Finding of endocannabinoids in human eye tissues: implications for glaucoma. Biochem. Biophys. Res. Commun., 2005, 330(4), 1062-1067.
104. Matias, I.; Gonthier, M.P.; Petrosino, S.; Docimo, L.; Capasso, R.; Hoareau, L.; Monteleone, P.; Roche, R.; Izzo, A.A.; Di Marzo, V. Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. Br. J. Pharmacol., 2007, 152(5), 676-690.
105. Walter, L.; Franklin, A.; Witting, A.; Moller, T.; Stella, N. Astrocytes in culture produce anandamide and other acylethanolamides. J. Biol. Chem., 2002, 277(23), 20869-20876.
106. Muccioli, G.G.; Stella, N. Microglia produce and hydrolyze palmitoylethanolamide. Neuropharmacology, 2008, 54(1), 16-22.
107. Di Marzo, V.; Fontana, A., Cadas, H.; Schinelli, S.; Cimino, G.; Schwartz, J.C.; Piomelli, D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 1994, 372(6507), 686-691.
108. Stella, N.; Piomelli, D. Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur J Pharmacol. 2001;425(3):189-196.
109. Darmani, N.A.; Izzo, A.A.; Degenhardt, B.; Valenti, M.; Scaglione, G.; Capasso, F.; Sorrentini, I.; Di Marzo, V. Involvement of the cannabimimetic compound, N-palmitoylethanolamine, in inflammatory and neuropathic conditions. A review of the available pre-clinical data and first human studies. Neuropharmacology, 2005, 48(8), 1154-1163.
110. Epps, D.E.; Schmid, P.C.; Natarajan, V.; Schmid, H.H. NAcylethanolamine accumulation in infarcted myocardium. Biochem. Biophys. Res. Commun., 1979, 90(2), 628-633.
111. Kallendrusch, S.; Koch, M.; Grabiec, U.; Dehghani, F. Perforant pathway transsection induces differential regulation of endocannabinoid levels in organotypic hippocampal slice cultures. Proceedings ICRS 2010 - 20th Annual Symposium of the International Cannabinoid Research Society, 2010, Lund, Sweden
112. Schäbitz, W.R.; Giuffrida, A.; Berger, C.; Aschoff, A.; Schwaninger, M.; Schwab, S.; Piomelli, D. Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke, 2002, 33(8), 2112-2114.
113. Garcia-Ovejero, D.; Arevalo-Martin, A.; Petrosino, S.; Docagne, F.; Hagen, C.; Bisogno, T.; Watanabe, M.; Guaza, C.; Di Marzo, V.; Molina-Holgado, E. The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol. Dis., 2009, 33(1), 57-71.
114. Franklin, A.; Parmentier-Batteur, S.; Walter, L.; Greenberg, D.A.; Stella, N. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J. Neurosci., 2003, 23(21), 7767-7775.
115. Capasso, R.; Izzo, A.A.; Fezza F.; Pinto, A.; Capasso, F.; Mascolo, N.; Di Marzo, V. Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br. J. Pharmacol., 2001, 134(5), 945-950.
116. De Filippis, D.; D'Amico, A.; Cipriano, M.; Petrosino, S.; Orlando, P.; Di Marzo, V.; Iuvone, T., Endocannabinoid Research Group. Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. Pharmacol. Res. 2010, 61(4), 321-328.
117. Petrosino, S.; Albanese, F.; Abramo, F.; Di Marzo, V. Increased skin levels of the aliamide palmitoylethanolamide and other endogenous fatty acid amides in dogs with atopic dermatitis. 33rd Annual WSAVA/FECAVA Congress, Dublin, Ireland, 20th-24th August 2008, p. 707.
118. D'Argenio, G.; Petrosino, S.; Gianfrani, C.; Valenti, M.; Scaglione, G.; Grandone, I.; Nigam, S.; Sorrentini, I.; Mazzarella, G.; Di Marzo, V. Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J. Mol. Med., 2007, 85(5), 523-530.
119. th Annual Symposium of the International Cannabinoid Research Society, 2010, Lund, Sweden.
120. Izzo, A.A.; Aviello, G.; Petrosino, S.; Orlando, P.; Marsicano, G.; Lutz, B.; Borrelli, F.; Capasso, R.; Nigam, S.; Capasso, F.; Di Marzo, V. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J. Mol. Med., 2008, 86(1), 89-98.
121. Berdyshev, E.V.; Schmid, P.C.; Dong, Z.; Schmid, H.H. Stressinduced generation of N-acylethanolamines in mouse epidermal JB6 P+ cells. Biochem. J., 2000, 2, 369-374.
122. Hsu, C.L.; Neilsen, C.V.; Bryce, P.J. IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS One, 2010, 5(8), e11944.
123. Kinet, J.P. The essential role of mast cells in orchestrating inflammation. Immunol. Rev., 2007, 217, 5-7.
124. Theoharides, T.C.; Kempuraj, D.; Tagen, M.; Conti, P.; Kalogeromitros, D. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol. Rev., 2007, 217, 65-78
125. Lindsberg, P.J.; Strbian, D.; Karjalainen-Lindsberg, M.L. Mast cells as early responders in the regulation of acute blood-brain barrier changes after cerebral ischemia and hemorrhage. J. Cereb. Blood Flow Metab., 2010, 30(4), 689-702.
126. Yuan, H.; Zhu, X.; Zhou, S.; Chen, Q.; Zhu, X.; Ma, X.; He, X.; Tian, M.; Shi, X. Role of mast cell activation in inducing microglial cells to release neurotrophin. J. Neurosci. Res., 2010, 88(6), 1348-1354.
127. Ziemssen, T.; Kern, S. Psychoneuroimmunology cross-talk between the immune and nervous systems. J. Neurol., 2007, 254(2), II8-11.
128. Berdyshev, E.V.; Boichot, E.; Germain, N.; Allain, N.; Anger, J.P.; Lagente, V. Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur. J. Pharmacol., 1997, 330(2-3), 231-240.
129. Ross, R.A.; Brockie, H.C.; Pertwee, R.G. Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. Eur. J. Pharmacol., 2000, 401(2), 121-130.
130. Berdyshev, E.V.; Boichot, E.; Corbel, M.; Germain, N.; Lagente, V. Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. Life Sci., 1998, 63(8), PL125-129.
131. Yoshihara, S.; Morimoto, H.; Ohori, M.; Yamada, Y.; Abe, T.; Arisaka, O. Endogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea pig airways. Int. Arch. Allergy Immunol., 2005, 138(1), 80-7.
132. Mazzari, S.; Canella, R.; Petrelli, L.; Marcolongo, G.; Leon, A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. J. Pharmacol., 1996, 300(3), 227-236.
133. D'Agostino, G.; La Rana, G.; Russo, R.; Sasso, O.; Iacono, A.; Esposito, E.; Mattace Raso, G.; Cuzzocrea, S.; Lo Verme, J.; Piomelli, D.; Meli, R.; Calignano, A. Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous PPAR-{alpha} agonist, modulates carrageenan-induced paw edema in mice. J. Pharmacol. Exp. Ther., 2007, 322(3), 1137-1143.
134. Solorzano, C.; Zhu, C.; Battista, N.; Astarita, G.; Lodola, A.; Rivara, S.; Mor, M.; Russo, R.; Maccarrone, M.; Antonietti, F.; Duranti, A.; Tontini, A.; Cuzzocrea, S.; Tarzia, G.; Piomelli, D. Selective Nacylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc. Natl. Acad. Sci. U S A., 2009, 106(49), 20966-20971.
135. Loría, F.; Petrosino, S.; Mestre, L.; Spagnolo, A.; Correa, F.; Hernangómez, M.; Guaza, C.; Di Marzo, V.; Docagne, F. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur. J. Neurosci., 2008, 28(4), 633-641.
136. De Filippis, D.; Luongo, L.; Cipriano, M.; Palazzo, E.; Cinelli, M.P.; de Novellis, V.; Maione, S.; Iuvone, T. Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. Mol. Pain., 2011, 7(3).
137. Calignano, A.; La Rana, G.; Piomelli, D. Antinociceptive activity of the endogenous fatty acid amide, palmitoylethanolamide. Eur. J. Pharmacol, 2001, 419(2-3), 191-198.
138. Rodríguez de Fonseca, F.; Navarro, M.; Gómez, R.; Escuredo, L.; Nava, F.; Fu, J.; Murillo-Rodríguez, E.; Giuffrida, A.; LoVerme, J.; Gaetani, S.; Kathuria, S.; Gall, C; Piomelli, D. An anorexic lipid mediator regulated by feeding. Nature, 2001, 414(6860), 209-212.
139. Sheerin, A.H.; Zhang, X.; Saucier, D.M.; Corcoran, M.E. Selective antiepileptic effects of N-palmitoylethanolamide, a putative endocannabinoid. Epilepsia, 2004, 45(10), 1184-1188.
140. Natarajan, V.; Schmid, P.C.; Schmid, H.H. N-acylethanolamine phospholipid metabolism in normal and ischemic rat brain. Biochim. Biophys. Acta, 1986, 878(1), 32-41.
141. Petrosino, S.; Palazzo, E.; de Novellis, V.; Bisogno, T.; Rossi, F.; Maione, S.; Di Marzo, V. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology, 2007, 52(2), 415-422.
142. Costa, B.; Comelli, F.; Bettoni, I.; Colleoni, M.; Giagnoni, G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and antihyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPARgamma receptors and neurotrophic factors. Pain, 2008, 139(3), 541-550.
143. Ben-Shabat, S.; Fride, E.; Sheskin, T.; Tamiri, T.; Rhee, M.H.; Vogel, Z.; Bisogno, T.; De Petrocellis, L.; Di Marzo, V.; Mechoulam, R. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol, 1998, 353(1), 23-31.
144. Genovese, T.; Esposito, E.; Mazzon, E.; Di Paola, R.; Meli, R.; Bramanti, P.; Piomelli, D.; Calignano, A.; Cuzzocrea, S. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J. Pharmacol. Exp. Ther., 2008, 326(1), 12-23.
145. Esposito, E.; Paterniti, I.; Mazzon, E.; Genovese, T.; Di Paola, R.; Galuppo, M.; Cuzzocrea, S. Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. Brain Behav. Immun., 2011, 25(6), 1099-1112.
146. Scuderi, C; Esposito, G.; Blasio, A.; Valenza, M.; Arietti, P.; Steardo, L.Jr.; Carnuccio, R.; De Filippis, D.; Petrosino, S.; Iuvone, T.; Di Marzo, V.; Steardo, L. Palmitoylethanolamide counteracts reactive astrogliosis induced by beta-amyloid peptide. J. Cell Mol Med., 2011, 15(12), 2664-2674.
147. Mattace Raso, G.; Esposito, E.; Vitiello, S.; Iacono, A.; Santoro, A.; D'Agostino, G.; Sasso, O.; Russo, R.; Piazza, P.V.; Calignano, A.; Meli, R. Palmitoylethanolamide stimulation induces allopregnanolone synthesis in C6 cells and primary astrocytes: involvement of peroxisome-proliferator activated receptor-a. J. Neuroendocrinol, 2011, 23(7), 591-600.
148. Kilaru, A.; Blancaflor, E.B.; Venables, B.J.; Tripathy, S.; Mysore, K.S.; Chapman, K.D. The N-acylethanolamine-mediated regulatory pathway in plants. Chem. Biodivers., 2007, 4(8), 1933-1955.
149. Sepe, N; De Petrocellis, L.; Montanaro, F.; Cimino, G.; Di Marzo, V. Bioactive long chain N-acylethanolamines in five species of edible bivalve molluscs. Possible implications for mollusc physiology and sea food industry. Biochim. Biophys. Acta, 1998, 1389(2), 101-111.
150. Schmid, P.C.; Krebsbach, R.J.; Perry, S.R.; Dettmer, T.M.; Maasson, J.L.; Schmid, H.H. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett., 1995, 375(1-2), 117-120.
151. Artmann, A.; Petersen, G.; Hellgren, L.I.; Boberg, J.; Skonberg, C; Nellemann, C; Hansen S.H.; Hansen, H.S. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim. Biophys. Acta, 2008, 1781(4), 200-212.
152. Baker, D.; Pryce, G.; Croxford, J.L.; Brown, P.; Pertwee, R.G.; Makriyannis, A.; Khanolkar, A.; Layward, L.; Fezza, F.; Bisogno, T.; Di Marzo, V. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J., 2001, 15(2), 300-302.
153. Richardson, D.; Ortori, C.A.; Chapman, V.; Kendall, DA.; Barrett, DA. Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry. Anal Biochem., 2007, 360(2), 216-226.
154. Rubio, M.; McHugh, D.; Fernández-Ruiz, J.; Bradshaw, H.; Walker, J.M. Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoylglycerol. Neurosci. Lett., 2007, 421(3), 270-4.
155. Annuzzi, G.; Piscitelli, F.; Di Marino, L.; Patti, L.; Giacco, R.; Costabile, G.; Bozzetto, L.; Riccardi, G.; Verde, R.; Petrosino, S.; Rivellese, A.A.; Di Marzo, V. Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. Lipids Health Dis., 2010, 9, 43.
156. Maccarrone, M.; Fride, E.; Bisogno, T.; Bari, M.; Cascio, M.G.; Battista, N.; Finazzi Agrò, A.; Suris, R., Mechoulam, R.; Di Marzo V. Upregulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. Mol. Hum. Reprod., 2005, 11(1), 21-28.
157. Di Sabatino, A.; Battista, N.; Biancheri, P.; Rapino, C.; Rovedatti, L.; Astarita, G.; Vanoli, A.; Dainese, E.; Guerci, M.; Piomelli, D.; Pender, S.L.; MacDonald, T.T.; Maccarrone, M.; Corazza, G.R. The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. Mucosal Immunol., 2011, 4(5), 574-583.
158. Nichols, K.K.; Ham, B.M.; Nichols, J.J.; Ziegler, C.; Green-Church, K.B. Identification of fatty acids and fatty acid amides in human meibomian gland secretions. Invest. Ophthalmol. Vis. Sci., 2007, 48(1), 34-39.
159. Guindon, J.; Loverme, J.; De Lean, A.; Piomelli, D.; Beaulieu, P. Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: A role for endogenous fatty-acid ethanolamides? Eur. J. Pharmacol., 2006, 550(1-3), 68-77.
160. Zolese, G.; Bacchetti, T.; Ambrosini, A.; Wozniak, M.; Bertoli, E.; Ferretti, G. Increased plasma concentrations of palmitoylethanolamide, an endogenous fatty acid amide, affect oxidative damage of human low-density lipoproteins: an in vitro study. Atherosclerosis, 2005, 182(1), 47-55.
161. Schreiber, D.; Harlfinger, S.; Nolden, B.M.; Gerth, C.W.; Jaehde, U.; Schomig, E.; Klosterkotter, J.; Giuffrida, A.; Astarita, G.; Piomelli, D.; Markus Leweke, F. Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry. Anal. Biochem., 2007, 361(2), 162-168.
162. Hill, M.N.; Miller, G.E.; Carrier, E.J.; Gorzalka, B.B.; Hillard, C.J. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology, 2009, 34(8), 1257-1262.
163. Ozalp, A.; Barroso, B. Simultaneous quantitative analysis of nacylethanolamides in clinical samples. Anal. Biochem., 2009, 395(1), 68-76.
164. Balvers, M.G.J.; Verhoeckx, K.C.M.; Witkamp, R.F. Development and validation of a quantitative method for the determination of 12 endocannabinoids and related compounds in human plasma using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2009, 877(14-15), 1583-1590.
165. Jumpertz, R.; Guijarro, A.; Pratley, R.E.; Piomelli, D.; Krakoff, J. Central and peripheral endocannabinoids and cognate acylethanolamides in humans: association with race, adiposity, and energy expenditure. J. Clin. Endocrinol. Metab., 2011, 96(3), 787-791.
166. Sharma, K.; Singh, R.R.; Kandaswamy, M.; Mithra, C.; Giri, S.; Rajagopal, S.; Mullangi, R. LC-MS/MS-ESI method for simultaneous quantitation of three endocannabinoids and its application to rat pharmacokinetic studies. Bioanalysis, 2011, 3(2), 181-196.
167. Giuffrida, A.; Piomelli, D. Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. FEBS Lett., 1998, 422(3), 373-376.
168. Sarchielli, P.; Pini, L.A.; Coppola, F.; Rossi, C.; Baldi, A.; Mancini, M.L.; Calabresi, P. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology, 2007, 32(6), 1384-1390.
169. Berger, C.; Schmid, P.C.; Schabitz, W.R.; Wolf, M.; Schwab, S.; Schmid, H.H. Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J. Neurochem., 2004, 88(5), 1159-1167.